spacer
home > ict > spring 2020 > pushing ‘go’ again on clinical trials in a post-covid-19 world
PUBLICATIONS
International Clinical Trials

Pushing ‘Go’ Again on Clinical Trials in a Post-COVID-19 World



When the word ‘coronavirus’ entered the general consciousness in early 2020, little did we know the extent to which this new disease would essentially press pause on our daily lives. The true ramifications of lockdowns, social distancing, self-isolation, as well as hospital closures caused by the pandemic are as yet unknown, and will likely reverberate for a generation.

What we do know is across several weeks of firefighting to respond to the immediate situation, clinical trial sponsors have not yet got to thinking about what happens next. Clearly the current challenges are daunting. There’s a lot that needs to happen before we start thinking about patients travelling to sites again for their regular visits, but it’s worth starting to consider what happens when pharma companies do decide to press the ‘go’ button again.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the company

Illingworth Research Group is a provider of patient-centric clinical research solutions. This can be, but is not exclusive to, mobile research nursing, patient concierge, and medical photography. Services are operational in 45 countries and concentrate on taking the trial to the patient or making trial participation easier and more accessible to patients and their families. illingworthresearch.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

SPRAVATO®▼ (esketamine nasal spray) data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1

November 23, 2022 -- BEERSE, Belgium--(BUSINESS WIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from ESCAPE-TRD, a long-term, comparative, randomised, open-label phase 3b clinical trial designed to evaluate the short- and long-term efficacy, safety and tolerability of flexibly dosed SPRAVATO® (esketamine nasal spray [NS]) compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI), in adults with treatment-resistant major depressive disorder (TRD). The findings, presented today at the German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) Congress, showed that esketamine NS met its primary endpoint, demonstrating superior efficacy in achieving remission at Week 8 compared to quetiapine XR. The study also met its key secondary endpoint, demonstrating that not only did significantly more participants treated with esketamine NS compared to quetiapine XR achieve remission while on study treatment at Week 8, they also remained relapse free up to Week 32.
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement